Silverback Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $86,581 | $2,068 | $500 | $0 |
Gross Profit | 85,716 | 1,956 | 482 | -11 |
EBITDA | 47,197 | -21,748 | -15,322 | -13,181 |
EBIT | 47,226 | -15,340 | -13,192 | |
Net Income | 49,934 | -19,128 | -12,516 | -10,292 |
Net Change In Cash | 86,581 | 2,068 | 500 | 0 |
Free Cash Flow | 41,702 | -14,607 | -7,317 | -6,793 |
Cash | 50,817 | 39,657 | 36,626 | 56,006 |
Basic Shares | 102,390 | 97,032 | 96,827 | 96,486 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $89,149 | $30 | $1,316 | $5,506 |
Gross Profit | 89,149 | -43 | -16,004 | -14,767 |
EBITDA | -3,083 | -67,447 | -35,516 | -19,241 |
EBIT | -67,520 | -35,835 | -19,454 | |
Net Income | 7,998 | -54,365 | -33,988 | -20,243 |
Net Change In Cash | 89,149 | 30 | 1,316 | 5,506 |
Cost of Revenue | 150,455 | |||
Free Cash Flow | 12,985 | -59,441 | -40,277 | -17,616 |
Cash | 50,817 | 70,971 | 210,518 | 60,063 |
Basic Shares | 102,390 | 95,215 | 39,956 | 28,872 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | $0.51 |
2024-09-30 | -$0.20 |
2024-06-30 | -$0.13 |
2024-03-31 | -$0.11 |
